The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Pediatrix Medical Group Inc (NYSE: MD) closed the day trading at $13.35 down -0.45% from the previous closing price of $13.41. In other words, the price has decreased by -$0.45 from its previous closing price. On the day, 0.59 million shares were traded. MD stock price reached its highest trading level at $13.49 during the session, while it also had its lowest trading level at $13.23.
Ratios:
For a better understanding of MD, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.23 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.90. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 1.81. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.79.
On September 26, 2024, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $8 to $14.
Deutsche Bank Upgraded its Sell to Hold on June 07, 2024, while the target price for the stock was maintained at $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 21 ’25 when Swift James D bought 18,530 shares for $16.63 per share.
ORDAN MARK S sold 27,600 shares of MD for $423,660 on Nov 13 ’24. The Director now owns 138,683 shares after completing the transaction at $15.35 per share. On Nov 13 ’24, another insider, ORDAN MARK S, who serves as the Director of the company, bought 27,600 shares for $15.50 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MD now has a Market Capitalization of 1146841088 and an Enterprise Value of 1560336384. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.58 while its Price-to-Book (P/B) ratio in mrq is 1.45. Its current Enterprise Value per Revenue stands at 0.79 whereas that against EBITDA is 6.927.
Stock Price History:
The Beta on a monthly basis for MD is 1.27, which has changed by 0.73151755 over the last 52 weeks, in comparison to a change of 0.092761636 over the same period for the S&P500. Over the past 52 weeks, MD has reached a high of $17.67, while it has fallen to a 52-week low of $6.62. The 50-Day Moving Average of the stock is -2.47%, while the 200-Day Moving Average is calculated to be -1.71%.
Shares Statistics:
Over the past 3-months, MD traded about 881.51K shares per day on average, while over the past 10 days, MD traded about 683070 shares per day. A total of 85.81M shares are outstanding, with a floating share count of 84.40M. Insiders hold about 1.76% of the company’s shares, while institutions hold 88.71% stake in the company. Shares short for MD as of 1748563200 were 1737300 with a Short Ratio of 1.97, compared to 1745971200 on 1949793. Therefore, it implies a Short% of Shares Outstanding of 1737300 and a Short% of Float of 2.8399997999999997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A detailed examination of Pediatrix Medical Group Inc (MD) is currently in progress, with 8.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.44, with high estimates of $0.48 and low estimates of $0.41.
Analysts are recommending an EPS of between $1.73 and $1.6 for the fiscal current year, implying an average EPS of $1.67. EPS for the following year is $1.72, with 8.0 analysts recommending between $1.84 and $1.6.
Revenue Estimates
8 analysts predict $464.37M in revenue for the current quarter. It ranges from a high estimate of $490.01M to a low estimate of $446.81M. As of the current estimate, Pediatrix Medical Group Inc’s year-ago sales were $504.3MFor the next quarter, 8 analysts are estimating revenue of $472.84M. There is a high estimate of $506.92M for the next quarter, whereas the lowest estimate is $452.89M.
A total of 8 analysts have provided revenue estimates for MD’s current fiscal year. The highest revenue estimate was $1.96B, while the lowest revenue estimate was $1.85B, resulting in an average revenue estimate of $1.87B. In the same quarter a year ago, actual revenue was $2.01BBased on 8 analysts’ estimates, the company’s revenue will be $1.93B in the next fiscal year. The high estimate is $2.02B and the low estimate is $1.85B.
